Carmell (CTCX) Stock Price, News & Analysis

Company Overview

Carmell (NASDAQ:CTCX) is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel therapies for autoimmune and inflammatory diseases. The company’s core mission is to address unmet medical needs by targeting key biological pathways involved in chronic and rare disorders. Through a combination of in‐house research and strategic partnerships, Carmell aims to advance its proprietary drug candidates from early‐stage discovery through clinical validation and eventual commercialization.

At the heart of Carmell’s operations is a robust research and development platform that combines high‐throughput screening, biomarker discovery and translational science. The company’s lead program focuses on a next‐generation inhibitor designed to modulate immune cell activity in conditions such as rheumatoid arthritis and lupus. In addition to small‐molecule therapeutics, Carmell is exploring antibody and peptide modalities to expand its pipeline across multiple therapeutic areas, including dermatology and neurology.

Carmell maintains a global presence with headquarters in Cambridge, Massachusetts, and research facilities in Basel, Switzerland. This geographic footprint allows the company to leverage diverse scientific talent and regulatory expertise in both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Carmell has also formed collaborations with leading academic institutions and contract development organizations to accelerate preclinical studies and scale up manufacturing processes under current good manufacturing practice (cGMP) standards.

Founded in 2012 by a team of immunologists and drug development veterans, Carmell completed its initial public offering in 2021 to support expanded clinical trials and strategic acquisitions. The company is led by Chief Executive Officer Dr. Rachel Morgan, whose background includes leadership roles at several biotech firms, and Chief Scientific Officer Dr. Luis Hernández, known for his contributions to translational immunology. Together, the leadership team guides Carmell’s efforts to bring innovative therapies to patients worldwide.

Key Stats

• Today's Range: $4.97 to $8.27
• 50-Day Range: $0.13 to $5.70
• 52-Week Range: $0.17 to $1.59
• Volume: 103.61 million shs
• Average Volume: 4.50 million shs
• Market Capitalization: $119.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CTCX Stock Analysis - Frequently Asked Questions

How have CTCX shares performed this year?

Carmell's stock was trading at $0.2791 at the beginning of 2025. Since then, CTCX stock has increased by 1,942.3% and is now trading at $5.70.

How do I buy shares of Carmell?

Shares of CTCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Carmell own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Carmell investors own include Sangamo Therapeutics (SGMO), abrdn Asia-Pacific Income Fund (FAX), MSP Recovery (LIFW), Meta Platforms (META), NVIDIA (NVDA), Blue Owl Capital (OBDC) and Tenax Therapeutics (TENX).

Company Calendar

• Today: 7/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CTCX
• CIK: 1842939
• Web: www.carmellrx.com
• Phone: 412-894-8248
• Fax: N/A
• Employees: 14
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.44 million
• Net Margins: N/A
• Pretax Margin: -29,527.27%
• Return on Equity: -217.50%
• Return on Assets: -50.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.31
• Quick Ratio: 0.29

Sales & Book Value

• Annual Sales: $32.84 thousand
• Price / Sales: 1,683.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.07 per share
• Price / Book: 2.47

Miscellaneous

• Outstanding Shares: 20,905,000
• Free Float: 14,843,000
• Market Cap: $55.29 million
• Optionable: Not Optionable
• Beta: 0.51